<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">LDFc4RjmQBZHk3NG3XvtT7M</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012000400016</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09800416</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012000400016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Ponto de Vista</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>S&#237;ndrome ou pseudoss&#237;ndrome metab&#243;lica?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Correia</surname>
            <given-names>Luis Cl&#225;udio Lemos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Latado</surname>
            <given-names>Adriana L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barreto-Filho</surname>
            <given-names>Jos&#233; Augusto</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">Bahia</named-content>
        </addr-line>
        <institution content-type="orgname">Escola Bahiana de Medicina e Sa&#250;de P&#250;blica</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
          <named-content content-type="state">Bahia</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal da Bahia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Aracaju</named-content>
          <named-content content-type="state">Sergipe</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de Sergipe</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2012</year>
      </pub-date>
      <volume>98</volume>
      <issue>4</issue>
      <fpage>e74</fpage>
      <lpage>e75</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>09</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>09</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>S&#237;ndrome metab&#243;lica tem sido proposta como preditor de risco cardiovascular. No entanto, esta id&#233;ia n&#227;o possui forte embasamento cient&#237;fico. O presente artigo revisa as evid&#234;ncias a este respeito, questionando o paradigma vigente do valor progn&#243;stico da s&#237;ndrome metab&#243;lica.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Fatores de risco</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>obesidade</kwd>
        <kwd>circunfer&#234;ncia abdominal</kwd>
        <kwd>progn&#243;stico</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>21</day>
        <month>06</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>PONTO DE VISTA</bold>
    </p>
    <p>
      <bold>S&#237;ndrome ou pseudoss&#237;ndrome metab&#243;lica?</bold>
    </p>
    <p>
      <bold>Luis Cl&#225;udio Lemos Correia<sup>I</sup>; Adriana L. Latado<sup>II</sup>; Jos&#233; Augusto Barreto-Filho<sup>III</sup></bold>
    </p>
    <p><sup>I</sup>Escola Bahiana de Medicina, Brasil </p>
    <p><sup>II</sup>Universidade Federal da Bahia, Salvador/BA, Brasil </p>
    <p><sup>III</sup>Universidade Federal de Sergipe, Aracaju, SE, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>S&#237;ndrome metab&#243;lica tem sido proposta como preditor de risco cardiovascular. No entanto, esta id&#233;ia n&#227;o possui forte embasamento cient&#237;fico. O presente artigo revisa as evid&#234;ncias a este respeito, questionando o paradigma vigente do valor progn&#243;stico da s&#237;ndrome metab&#243;lica. </p>
    <p><bold>Palavras-chave</bold> Fatores de risco, diabetes mellitus, obesidade, circunfer&#234;ncia abdominal, progn&#243;stico.</p>
    <p>Conta a hist&#243;ria de Hans Christian Andersen (1937) que um rei muito vaidoso encomendou de dois alfaiates uma roupa sem precedentes, de qualidade t&#227;o especial que nunca algu&#233;m tivesse vestido igual. Na impossibilidade de concretizar tal desejo, os alfaiates idealizaram uma roupa maravilhosa, por&#233;m invis&#237;vel aos olhos de pessoas est&#250;pidas. O pr&#243;prio rei, ao experimentar a roupa, n&#227;o conseguiu visualiz&#225;-la no espelho, por&#233;m fingiu que estava vendo para n&#227;o parecer est&#250;pido. Da mesma forma, todas as pessoas percebiam que o rei estava nu, por&#233;m ningu&#233;m lhe chamava a aten&#231;&#227;o pelo receio de ser rotulado de est&#250;pido. E assim o rei passou boa parte de seu reinado nu, exposto ao rid&#237;culo. </p>
    <p>Essa hist&#243;ria retrata o porqu&#234; de alguns mitos m&#233;dicos perdurarem por longos anos, embora sem fundamenta&#231;&#227;o cient&#237;fica. S&#237;ndrome metab&#243;lica como uma entidade de grande valor cl&#237;nico nos parece um mito a ser questionado. Na verdade, essa entidade guarda uma enorme dissocia&#231;&#227;o entre sua popularidade e sua real utilidade na tomada de decis&#227;o m&#233;dica. S&#237;ndrome metab&#243;lica pode ser definida como a constela&#231;&#227;o de pelo menos tr&#234;s dos cinco crit&#233;rios: aumento de circunfer&#234;ncia abdominal, triglic&#233;rides elevados, HDL-colesterol baixo, press&#227;o arterial elevada e glicemia <underline>&gt;</underline> 100 mg/dl<sup>1</sup>. Tal conceito tomou grande dimens&#227;o com o trabalho seminal de Reaven<sup>2</sup>, ao propor modelo fisiopatol&#243;gico no qual a resist&#234;ncia insul&#237;nica/hiperinsulinemia seria o elo respons&#225;vel pelo <italic>cluster</italic> de fatores de risco cardiovascular comumente observados na pratica cl&#237;nica.</p>
    <p>Entretanto, a extrapola&#231;&#227;o dessa hip&#243;tese fisiopatol&#243;gica para a cria&#231;&#227;o de um conceito de s&#237;ndrome metab&#243;lica utilizado na predi&#231;&#227;o de eventos cardiovasculares e de desenvolvimento de diabetes n&#227;o &#233; bem fundamentada e exemplifica como mitos podem ser criados. Portanto, o objetivo dessa breve revis&#227;o &#233; analisar, sob a &#243;tica de evid&#234;ncias cient&#237;ficas, se s&#237;ndrome metab&#243;lica realmente merece tal cr&#233;dito.</p>
    <p>Um modelo preditor &#233; criado a partir da (1) identifica&#231;&#227;o de vari&#225;veis associadas ao desfecho em estudos de coorte, as quais ser&#227;o submetidas a (2) an&#225;lise multivariada que define quais s&#227;o os preditores independentes do desfecho e o valor relativo de cada um deles. De posse desses dados, (3) esses preditores recebem uma pontua&#231;&#227;o proporcional &#224; sua for&#231;a de associa&#231;&#227;o com o desfecho, gerando um escore de risco. Assim foi criado o cl&#225;ssico Escore de Framingham<sup>3</sup>. </p>
    <p>Em contraste, a s&#237;ndrome metab&#243;lica n&#227;o foi criada a partir da associa&#231;&#227;o independente de cada um de seus componentes com o desfecho. Em uma estrat&#233;gia mais simples, especialistas agruparam achados cl&#237;nicos e laboratoriais sob a premissa de um construto fisiopatol&#243;gico &#250;nico, no qual a resist&#234;ncia &#224; insulina forneceria o elo explicativo para as diferentes anormalidades metab&#243;licas. Isto tem pouca ou nenhuma rela&#231;&#227;o com predi&#231;&#227;o de risco. E por este motivo, estudos demonstram que a ;acur&#225;cia progn&#243;stica do Escore de Framingham &#233; nitidamente superior &#224; da s&#237;ndrome metab&#243;lica ;na predi&#231;&#227;o de eventos cardiovasculares, e o &#250;ltimo n&#227;o agrega valor progn&#243;stico ao primeiro<sup>3-5</sup>. </p>
    <p>Stern e cols.<sup>4</sup> avaliaram o valor progn&#243;stico desses dois modelos em rela&#231;&#227;o a eventos cardiovasculares, em uma coorte de 1.709 indiv&#237;duos n&#227;o diab&#233;ticos<sup>4</sup>. Na an&#225;lise univariada, o <italic>odds ratio</italic> do Escore de Framingham foi 9,7 (95% intervalo de confian&#231;a [IC] = 6,7 - 14), nitidamente superior ao <italic>odds ratio</italic> de 4,0 (95% IC = 2,8 - 5,6) da <italic>s&#237;ndrome metab&#243;lica</italic>. Ainda mais relevante, quando ambos os modelos preditores foram colocados em an&#225;lise multivariada, o Escore de Framingham permaneceu com <italic>odds ratio</italic> de 9,1 (95% IC = 6,0 - 14), enquanto <italic>s&#237;ndrome metab&#243;lica</italic> perdeu signific&#226;ncia estat&#237;stica (<italic>odds ratio</italic> = 1,1; 95% IC = 0,76 - 1,7). Da mesma forma, a &#225;rea abaixo da curva <italic>receiver operating characteristic</italic> (ROC) do Escore de Framingham foi de 0,82, comparado a 0,81 ap&#243;s incorpora&#231;&#227;o do diagn&#243;stico de <italic>s&#237;ndrome metab&#243;lica</italic> ao modelo Framingham. Portanto, n&#227;o h&#225; qualquer valor progn&#243;stico incremental em se utilizar o diagn&#243;stico de s&#237;ndrome metab&#243;lica juntamente com o Escore de Framingham. </p>
    <p>Wannamethee e cols.<sup>5</sup> descreveram a &#225;rea abaixo da curva ROC do Escore de Framingham e do n&#250;mero de crit&#233;rios para s&#237;ndrome metab&#243;lica, em coorte de 5.128 homens do <italic>British Regional Heart Study<sup>5</sup></italic>. O Escore de Framingham apresentou &#225;rea abaixo da curva ROC de 0,73 (95% IC = 0,71 - 0,75), superior &#224; acur&#225;cia da s&#237;ndrome metab&#243;lica (0,63; 95% IC = 0,61 - 0,65) na predi&#231;&#227;o de eventos coronarianos (p &lt; 0,001). Da mesma forma, na coorte de 12.089 indiv&#237;duos do estudo <italic>Atherosclerosis Risk in Communities</italic> (ARIC), a &#225;rea abaixo da curva ROC do Escore de Framingham foi semelhante com ou sem a incorpora&#231;&#227;o da defini&#231;&#227;o de s&#237;ndrome metab&#243;lica, em mulheres (0,729 <italic>vs.</italic> 0,731) e homens (0,631 <italic>vs.</italic> 0,634)<sup>6</sup>. </p>
    <p>A excessiva valoriza&#231;&#227;o da s&#237;ndrome metab&#243;lica tem provocado certa confus&#227;o no racioc&#237;nio m&#233;dico. ;Um exemplo &#233; o equ&#237;voco da <italic>Diretriz Brasileira de Dislipidemia</italic> em sugerir que a presen&#231;a de s&#237;ndrome metab&#243;lica deve reclassificar pacientes de risco intermedi&#225;rio pelo Framingham para alto risco cardiovascular<sup>7</sup>. Neste contexto, foi recomendado que a presen&#231;a de s&#237;ndrome metab&#243;lica corrija a classifica&#231;&#227;o de Framingham. Por&#233;m &#233; question&#225;vel, e at&#233; mesmo surpreendente, que um melhor preditor seja corrigido pelo pior preditor. ;Principalmente quando o pior preditor n&#227;o agrega valor algum ao preditor tradicional<sup>4-6</sup>. </p>
    <p>Outro argumento que se utiliza a favor da s&#237;ndrome metab&#243;lica ;&#233; a predi&#231;&#227;o de desenvolvimento de diabetes. De fato, s&#237;ndrome metab&#243;lica ;prediz diabetes melhor do que o Escore de Framingham<sup>5</sup>. No entanto, quando se compara s&#237;ndrome metab&#243;lica ;com modelos criados para predi&#231;&#227;o de diabetes, estes &#250;ltimos apresentam melhor capacidade preditora do que a s&#237;ndrome metab&#243;lica<sup>4</sup>. Mais uma vez, isto &#233; o esperado, pois o agrupamento dos fatores de risco que definem o diagn&#243;stico de s&#237;ndrome metab&#243;lica n&#227;o est&#225; em acordo com os pressupostos cient&#237;ficos que embasam a cria&#231;&#227;o de modelos de predi&#231;&#227;o de risco. Desta forma, para predi&#231;&#227;o de diabetes o mais adequado s&#227;o modelos multivariados derivados de estudos de coorte. Neste contexto, &#233; digno de nota que a simples ;glicemia de jejum ;seja melhor preditor de diabetes do que a defini&#231;&#227;o de ;s&#237;ndrome metab&#243;lica. Por exemplo, na coorte do estudo PROSPER, o hazard ratio da s&#237;ndrome metab&#243;lica para predi&#231;&#227;o de diabetes foi 4,4, comparado a 18,4 da glicemia de jejum<sup>8</sup>. </p>
    <p>Exposto isto, deve-se questionar por que tanta &#234;nfase na s&#237;ndrome metab&#243;lica. A excessiva valoriza&#231;&#227;o desta s&#237;ndrome vem de nossa cultura em criar r&#243;tulos de doen&#231;as. A ;partir destes r&#243;tulos, exames complementares, medicamentos e procedimentos complexos s&#227;o justificados. Por exemplo, a droga anorex&#237;gena Rimonabant (j&#225; suspensa do mercado) teve seu marketing principal embasado na "cura" da s&#237;ndrome metab&#243;lica. Ao receber o r&#243;tulo de s&#237;ndrome metab&#243;lica, um procedimento como cirurgia bari&#225;trica, em algu&#233;m sem obesidade m&#243;rbida, pode parecer justific&#225;vel mesmo sem a valida&#231;&#227;o cient&#237;fica necess&#225;ria. Exames de pesquisa de isquemia mioc&#225;rdica podem parecer plaus&#237;veis quanto aplicados a um paciente com s&#237;ndrome metab&#243;lica, mesmo que assintom&#225;tico. E assim por diante. &#201; a medicaliza&#231;&#227;o da sociedade, induzida por r&#243;tulos de doen&#231;as.</p>
    <p>Assim, voltamos &#224; hist&#243;ria do rei. Um belo dia, durante um importante desfile em pra&#231;a p&#250;blica, ao ver o rei passar com a bela roupa, uma crian&#231;a gritou: o rei est&#225; nu! Essa crian&#231;a desmascarou a farsa criada pelos alfaiates, constrangeu o rei, e principalmente os s&#250;ditos que acreditaram na mentira ou ficaram com vergonha de discordar. Alguns interpretam que foi a inoc&#234;ncia da crian&#231;a que permitiu sua observa&#231;&#227;o. Na verdade, reza a lenda que esta era uma daquelas crian&#231;as um tanto maliciosas. Neste caso, a diferen&#231;a entre crian&#231;a e adulto que prevaleceu foi o reconhecimento da nua verdade. Em suma, a hist&#243;ria da S&#237;ndrome Metab&#243;lica nos ensina que nem sempre o conhecimento cientifico est&#225; embasado pelos seus pressupostos. S&#243; o questionamento e debate cientifico &#233; capaz de fazer o conhecimento avan&#231;ar.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Luis Cl&#225;udio Lemos Correia </p>
        <p> Av. Princesa Leopoldina 19/402- Gra&#231;a </p>
        <p> 40150-080 - Salvador, BA - Brasil </p>
        <p> E-mail:</p>
        <p><email xlink:href="lccorreia@cardiol.br">lccorreia@cardiol.br</email>, </p>
        <p>
          <email xlink:href="lccorreia@terra.com.br">lccorreia@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 20/09/11; revisado recebido em 21/09/11; aceito em 20/12/11. </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. <italic>Circulation.</italic> 2009;120(16):1640-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1640</fpage>
          <lpage>5</lpage>
          <issue>16</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alberti</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Eckel</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Grundy</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Zimmet</surname>
              <given-names>PZ</given-names>
            </name>
            <name>
              <surname>Cleeman</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Donato</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. <italic>Diabetes</italic> .1988;37(12):1595-607.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Banting lecture 1988: Role of insulin resistance in human disease</article-title>
          <source>Diabetes</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>1595</fpage>
          <lpage>607</lpage>
          <issue>12</issue>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Reaven</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. D'Agostino RB,  Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General Cardiovascular risk profile for use in primary care: The Framingham Heart Study. <italic>Circulation</italic> .2008;117(6):743-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>General Cardiovascular risk profile for use in primary care: The Framingham Heart Study</article-title>
          <source>Circulation</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>743</fpage>
          <lpage>53</lpage>
          <issue>6</issue>
          <volume>117</volume>
          <person-group person-group-type="author">
            <name>
              <surname>D'Agostino</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Vasan</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Pencina</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Cobain</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Massaro</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4.  Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? <italic>Diabetes Care</italic> .2004;27(11):2676-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2676</fpage>
          <lpage>81</lpage>
          <issue>11</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gonzalez-Villalpando</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Haffner</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Wannamethee SG, Shaper AG, Lennon L. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 Diabetes Mellitus. <italic>Arch Intern Med.</italic> 2005;165(22):2644-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 Diabetes Mellitus</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2644</fpage>
          <lpage>50</lpage>
          <issue>22</issue>
          <volume>165</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wannamethee</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Shaper</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Lennon</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The Metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. <italic>Diabetes Care</italic> .2005;28(2):385-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>385</fpage>
          <lpage>90</lpage>
          <issue>2</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McNeill</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Rosamond</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Girman</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Golden</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>East</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune NA, Souza AD, et al;/Brazilian Society of Cardiology. [IV Brazilian guideline for dyslipidemia and atherosclerosis prevention: <italic>Arq Bra.Cardiol.</italic> 2007;88( Suppl 1):2-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Brazilian guideline for dyslipidemia and atherosclerosis prevention</article-title>
          <source>Arq Bra.Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <lpage>19</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sposito</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Caramelli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Bertolami</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Afiune</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. <italic>Lancet.</italic> 2008;371(9628):1927-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Can metabolic syndrome usefully predict cardiovascular disease and diabetes?: Outcome data from two prospective studies</article-title>
          <source>Lancet</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1927</fpage>
          <lpage>35</lpage>
          <issue>9628</issue>
          <volume>371</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sattar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>McConnachie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shaper</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Blauw</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>de Craen</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Point of View</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Metabolic or pseudometabolic syndrome?</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Metabolic syndrome has been proposed as a predictor of cardiovascular risk. However, such idea lacks strong scientific basis. This article reviews the evidence regarding that issue, challenging the existing paradigm of the prognostic value of metabolic syndrome.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Risk factors</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>obesity</kwd>
        <kwd>abdominal circumference</kwd>
        <kwd>prognosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>POINT OF VIEW</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Metabolic or pseudometabolic syndrome?</bold>
          </label>
          <p>
            <bold>Luis Cl&#225;udio Lemos Correia<sup>I</sup>; Adriana L. Latado<sup>II</sup>; Jos&#233; Augusto Barreto-Filho<sup>III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Escola Bahiana de Medicina, Brazil</p>
      <p><sup>II</sup>Universidade Federal da Bahia, Salvador/BA,</p>
      <p><sup>III</sup>Universidade Federal de Sergipe, Aracaju, SE, Brazil</p>
      <p>Mailing Address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Metabolic syndrome has been proposed as a predictor of cardiovascular risk. However, such idea lacks strong scientific basis. This article reviews the evidence regarding that issue, challenging the existing paradigm of the prognostic value of metabolic syndrome.</p>
      <p><bold>Keywords:</bold> Risk factors; diabetes mellitus; obesity; abdominal circumference; prognosis.</p>
      <p>According to Hans Christian Andersen's tale (1837), once upon a time there lived a vain Emperor who ordered from two tailors an extraordinary suit, of such unique quality that nobody had ever seen a similar one. As the tailors could not fulfill the Emperor's wish, they conceived a wonderful suit, which would be invisible to anyone who was too stupid to appreciate its quality. The Emperor himself, while trying on his new clothes, could not see them on the mirror, but pretended to see them so as not to appear stupid. Similarly, everybody could see that the Emperor was naked, but nobody admitted it, since nobody was willing to admit his own stupidity. Thus, the Emperor spent a long time naked, exposed to ridicule.</p>
      <p>This tale explains why some medical myths last for so long, despite the lack of scientific basis. The metabolic syndrome, as an entity of great clinical value, seems to be a myth to be challenged. In reality, that entity holds a huge dissociation between its popularity and its real usefulness in medical decision making. The metabolic syndrome can be defined as the clustering of at least three of the following five criteria: increased abdominal circumference; high triglyceride levels; low HDL-cholesterol levels; high blood pressure; and glycemia <underline>&gt;</underline> 100 mg/dl<sup>1</sup>. That concept has gained importance with the seminal study by Reaven<sup>2</sup>, proposing a pathophysiological model in which insulin resistance/hyperinsulinemia would be the link responsible for the clustering of the cardiovascular risk factors commonly observed in clinical practice.</p>
      <p>However, extrapolating that pathophysiological hypothesis to the creation of a concept of metabolic syndrome used to predict cardiovascular events and the development of diabetes has not been well founded, exemplifying how myths can be created. Therefore, this brief review aimed at assessing, based on scientific evidence, whether metabolic syndrome really deserves credit for that.</p>
      <p><bold>Keywords:</bold> risk factors; diabetes mellitus; obesity; abdominal circumference; prognosis.</p>
      <p>A predictive model is created based on the following: (1) identification of variables associated with an outcome in cohort studies, which are submitted to (2) multivariate analysis that defines which are the independent predictors of outcome and the relative value of each one. Drawing on such data, (3) those predictors are attributed points proportionally to their force of association with the outcome, generating a risk score. That was how the classical Framingham Score was created<sup>3</sup>. </p>
      <p>Differently, the metabolic syndrome has not been created based on the independent association between outcome and each of those components. In a simpler strategy, experts have clustered clinical and laboratory findings based on the assumption of a single pathophysiological construct, in which insulin resistance would provide the explicative link for the different metabolic abnormalities. This has little if any relationship with risk prediction. In addition, studies have shown that the prognostic accuracy of the Framingham Score is clearly superior to that of the metabolic ;syndrome for predicting cardiovascular events, and that the latter does not add prognostic value to the former<sup>3-5</sup>. </p>
      <p>Stern et al<sup>4</sup> have assessed the prognostic value of those two models regarding cardiovascular events in a cohort of 1,709 non-diabetic individuals<sup>4</sup>. In the univariate analysis, the odds ratio of the Framingham Score was 9.7 (95% confidence interval [CI] = 6.7 - 14), clearly superior to that of the metabolic ;syndrome, 4.0 (95% CI = 2.8 - 5.6). Even more important, when both predictive models were tested using multivariate analysis, the Framingham Score remained with odds ratio of 9.1 (95% CI = 6.0 - 14), while the metabolic ;syndrome lost statistical significance (odds ratio = 1.1; 95% CI = 0.76 - 1.7). Similarly, the area under the receiver operating characteristic (ROC) curve of the Framingham Score was 0.82, as compared with 0.81 after incorporating the diagnosis of metabolic ;syndrome into the Framingham model. Thus, there is no incremental prognostic value in using the diagnosis of metabolic ;syndrome along with the Framingham Score. </p>
      <p>Wannamethee et al<sup>5</sup> have reported the area under the ROC curve of the Framingham Score and the number of criteria for the metabolic ;syndrome in a cohort of 5,128 men of the British Regional Heart Study<sup>5</sup>. The Framingham Score had an area under the ROC curve of 0.73 (95% CI = 0.71 - 0.75), greater than the accuracy of the metabolic ;syndrome (0.63; 95% CI = 0.61 - 0.65) in predicting coronary events (p &lt; 0.001). Likewise, in the cohort of 12,089 individuals of the Atherosclerosis Risk in Communities (ARIC) study, the area under the ROC curve of the Framingham Score was similar, with or without incorporating the definition of metabolic syndrome, in women (0.729 <italic>vs.</italic> 0.731) and men (0.631 <italic>vs.</italic> 0.634)<sup>6</sup>. </p>
      <p>The excessive attention given to metabolic ;syndrome has caused some confusion in medical reasoning. ;An example is the mistake of the Brazilian Guidelines on Dyslipidemia in suggesting that the presence of metabolic ;syndrome should reclassify patients at intermediate cardiovascular risk according to the Framingham Score to high risk<sup>7</sup>. In that context, it has been recommended that the presence of metabolic syndrome corrects the Framingham classification. However, it is questionable, and even surprising, that a better predictor be corrected by a worse predictor, especially when the worse predictor does not add any value to the traditional predictor<sup>4-6</sup>. </p>
      <p>Another argument used in favor of the metabolic ;syndrome is the prediction of the development of diabetes. In fact, metabolic ;syndrome predicts diabetes better than the Framingham Score<sup>5</sup>. However, when the metabolic ;syndrome is compared with models created to predict diabetes, the latter show better predictive capacity than metabolic syndrome<sup>4</sup>. Once again, that is expected, because the clustering of risk factors that define the diagnosis of metabolic ;syndrome is not in accordance with the scientific assumptions that have founded the creation of risk prediction models. Thus, for diabetes prediction, the most adequate are multivariate models derived from cohort studies. It is worth noting that the simple fasting ;glycemia is a better predictor of diabetes than the definition of ;metabolic syndrome. For example, in the cohort of the PROSPER study, the hazard ratio of the metabolic ;syndrome for predicting diabetes was 4.4 as compared with 18.4 of fasting glycemia<sup>8</sup>. </p>
      <p>Thus, one should question why so much emphasis on the metabolic ;syndrome. The excessive attention given to that syndrome originates from our culture of creating labels for diseases. Based on those labels, complementary tests, medications and complex procedures are justified. For example, the anorexigenic drug Rimonabant (already removed from the market) had its marketing campaign based on the "cure" of metabolic ;syndrome. When someone is labeled as having metabolic ;syndrome, a procedure such as bariatric surgery might seem justifiable in someone without morbid obesity, even without the necessary scientific validation. Tests to assess myocardial ischemia might seem plausible when applied to a patient with metabolic ;syndrome, even when asymptomatic. And so forth. That is medicalization of society induced by labels for diseases.</p>
      <p>Thus, returning to the tale of the Emperor's new clothes. One day, during a ceremonial parade in the streets of the village, when the Emperor passed wearing his "marvelous" clothes, one child shouted: the Emperor is naked! That child unveiled the tailors' trick, embarrassed the Emperor, and especially the people who believed in the lie or were ashamed to disagree. Some people say it was the child's innocence that allowed him/her to speak frankly. In reality, legend has it that the child was mischievous. In that case, the difference between the child and the adult was the recognition of the naked truth. Briefly, the tale of the Metabolic Syndrome teaches us that scientific knowledge is not always based on assumptions. Only questioning and scientific debate can make knowledge advance.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">&#191;S&#237;ndrome o seudos&#237;ndrome metab&#243;lico?</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>S&#237;ndrome metab&#243;lico ha sido propuesto como predictor de riesgo cardiovascular. Mientras tanto, esta idea no posee fuerte basamento cient&#237;fico. El presente art&#237;culo revisa las evidencias a este respecto, cuestionando el paradigma vigente del valor pron&#243;stico del s&#237;ndrome metab&#243;lico.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Factores de riesgo</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>obesidad</kwd>
        <kwd>circunferencia abdominal</kwd>
        <kwd>pron&#243;stico</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>PUNTO DE VISTA</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>&#191;S&#237;ndrome o seudos&#237;ndrome metab&#243;lico?</bold>
          </label>
          <p>
            <bold>Luis Cl&#225;udio Lemos Correia<sup>I</sup>; Adriana L. Latado<sup>II</sup>; Jos&#233; Augusto Barreto-Filho<sup>III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Escola Bahiana de Medicina, Brasil</p>
      <p> Universidade Federal da Bahia<sup>II</sup>, Salvador/BA, Brasil</p>
      <p> Universidade Federal de Sergipe<sup>III</sup>, Aracaju, SE, Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>S&#237;ndrome metab&#243;lico ha sido propuesto como predictor de riesgo cardiovascular. Mientras tanto, esta idea no posee fuerte basamento cient&#237;fico. El presente art&#237;culo revisa las evidencias a este respecto, cuestionando el paradigma vigente del valor pron&#243;stico del s&#237;ndrome metab&#243;lico. </p>
      <p><bold>Palabras clave:</bold> Factores de riesgo, diabetes mellitus, obesidad, circunferencia abdominal, pron&#243;stico.</p>
      <p>Cuenta la historia de Hans Christian Andersen (1837) que un rey muy vanidoso le encomend&#243; a dos sastres una ropa sin precedentes, de calidad tan especial que nunca nadie hubiese vestido algo igual. En la imposibilidad de concretar tal deseo, los sastres idealizaron una ropa maravillosa, sin embargo invisible a los ojos de personas est&#250;pidas. El mismo rey, al probarse la ropa, no logr&#243; verla en el espejo, sin embargo fingi&#243; que estaba viendo para no parecer est&#250;pido. De la misma forma, todas las personas percib&#237;an que el rey estaba desnudo, aunque nadie le llamaba la atenci&#243;n por el recelo de ser rotulado de est&#250;pido. Y as&#237; el rey pas&#243; buena parte de su reinado desnudo, expuesto al rid&#237;culo. </p>
      <p>Esa historia retrata el porqu&#233; de que algunos mitos m&#233;dicos perduren por largos a&#241;os, aun sin fundamentaci&#243;n cient&#237;fica. El s&#237;ndrome metab&#243;lico como una entidad de gran valor cl&#237;nico nos parece un mito a ser cuestionado. En verdad, esa entidad guarda una enorme disociaci&#243;n entre su popularidad y su real utilidad en la toma de decisi&#243;n m&#233;dica. El s&#237;ndrome metab&#243;lico puede ser definido como la constelaci&#243;n de por lo menos tres de los cinco criterios: aumento de circunferencia abdominal, triglic&#233;ridos elevados, HDL-colesterol bajo, presi&#243;n arterial elevada y glicemia <underline>&gt;</underline> 100 mg/dl<sup>1</sup>. Tal concepto tom&#243; gran dimensi&#243;n con el trabajo seminal de Reaven<underline><sup>2</sup></underline>, al proponer modelo fisiopatol&#243;gico en el cual la resistencia insul&#237;nica/hiperinsulinemia seria el eslab&#243;n responsable por el <italic>cluster</italic> de factores de riesgo cardiovascular com&#250;nmente observados en la pr&#225;ctica cl&#237;nica.</p>
      <p>Entre tanto, la extrapolaci&#243;n de esa hip&#243;tesis fisiopatol&#243;gica para la creaci&#243;n de un concepto de s&#237;ndrome metab&#243;lico utilizado en la predicci&#243;n de eventos cardiovasculares y de desarrollo de diabetes no est&#225; bien fundamentada y ejemplifica como mitos pueden ser creados. Por lo tanto, el objetivo de esa breve revisi&#243;n es analizar, bajo la &#243;ptica de evidencias cient&#237;ficas, si el s&#237;ndrome metab&#243;lico realmente merece tal cr&#233;dito.</p>
      <p>Un modelo predictor es creado a partir de la (1) identificaci&#243;n de variables asociadas al desenlace en estudios de cohorte, las cuales ser&#225;n sometidas a (2) an&#225;lisis multivariado que define cuales son los predictores independientes del desenlace y el valor relativo de cada uno de ellos. Con estos datos, (3) esos predictores reciben una puntuaci&#243;n proporcional a su fuerza de asociaci&#243;n con el desenlace, generando un escore de riesgo. As&#237; fue creado el cl&#225;sico Escore de Framingham<sup>3</sup>. </p>
      <p>En contraste, el s&#237;ndrome metab&#243;lico no fue creado a partir de la asociaci&#243;n independiente de cada uno de sus componentes con el desenlace. En una estrategia m&#225;s simple, especialistas agruparon hallazgos cl&#237;nicos y de laboratorio bajo la premisa de un constructo fisiopatol&#243;gico &#250;nico, en el cual la resistencia a la insulina proveer&#237;a el eslab&#243;n explicativo para las diferentes anormalidades metab&#243;licas. Esto tiene poca o ninguna relaci&#243;n con predicci&#243;n de riesgo. Y por este motivo, estudios demuestran que la ;precisi&#243;n pron&#243;stica del Escore de Framingham es n&#237;tidamente superior a la del s&#237;ndrome metab&#243;lico ;en la predicci&#243;n de eventos cardiovasculares, y el &#250;ltimo no agrega valor pron&#243;stico al primero<sup>3-5</sup>. </p>
      <p>Stern et al<sup>4</sup> evaluaron el valor pron&#243;stico de esos dos modelos en relaci&#243;n a eventos cardiovasculares, en una cohorte de 1.709 individuos no diab&#233;ticos<sup>4</sup>. En el an&#225;lisis univariado, el <italic>odds ratio</italic> del Escore de Framingham fue 9,7 (95% intervalo de confianza [IC] = 6,7 - 14), n&#237;tidamente superior al <italic>odds ratio</italic> de 4,0 (95% IC = 2,8 - 5,6) del <italic>s&#237;ndrome metab&#243;lico</italic>. Aun m&#225;s relevante, cuando ambos modelos predictores fueron colocados en an&#225;lisis multivariado, el Escore de Framingham permaneci&#243; con <italic>odds ratio</italic> de 9,1 (95% IC = 6,0 - 14), mientras que el <italic>s&#237;ndrome metab&#243;lico</italic> perdi&#243; significaci&#243;n estad&#237;stica (<italic>odds ratio</italic> = 1,1; 95% IC = 0,76 - 1,7). De la misma forma, el &#225;rea abajo de la curva <italic>receiver operating characteristic</italic> (ROC) del Escore de Framingham fue de 0,82, comparado a 0,81 despu&#233;s de incorporaci&#243;n del diagn&#243;stico de <italic>s&#237;ndrome metab&#243;lico</italic> al modelo Framingham. Por lo tanto, no hay ning&#250;n valor pron&#243;stico incremental en utilizar el diagn&#243;stico de s&#237;ndrome metab&#243;lico juntamente con el Escore de Framingham. </p>
      <p>Wannamethee et al<sup>5</sup> describieron el &#225;rea abajo de la curva ROC del Escore de Framingham y del n&#250;mero de criterios para s&#237;ndrome metab&#243;lico, en cohorte de 5.128 hombres del <italic>British Regional Heart Study</italic><sup>5</sup>. El Escore de Framingham present&#243; &#225;rea abajo de la curva ROC de 0,73 (95% IC = 0,71 - 0,75), superior a la precisi&#243;n del s&#237;ndrome metab&#243;lico (0,63; 95% IC = 0,61 - 0,65) en la predicci&#243;n de eventos coronarios (p &lt; 0,001). De la misma forma, en la cohorte de 12.089 individuos del estudio <italic>Atherosclerosis Risk in Communities</italic> (ARIC), el &#225;rea abajo de la curva ROC del Escore de Framingham fue semejante con o sin la incorporaci&#243;n de la definici&#243;n de s&#237;ndrome metab&#243;lico, en mujeres (0,729 <italic>vs.</italic> 0,731) y hombres (0,631 <italic>vs.</italic> 0,634)<sup>6</sup>. </p>
      <p>La excesiva valorizaci&#243;n del s&#237;ndrome metab&#243;lico ha provocado cierta confusi&#243;n en el razonamiento m&#233;dico. ;Un ejemplo es el equ&#237;voco de la <italic>Directriz Brasile&#241;a de Dislipidemia</italic> en sugerir que la presencia de s&#237;ndrome metab&#243;lico debe reclasificar pacientes de riesgo intermedio por el Framingham a alto riesgo cardiovascular<sup>7</sup>. En este contexto, fue recomendado que la presencia de s&#237;ndrome metab&#243;lico corrija la clasificaci&#243;n de Framingham. Sin embargo es cuestionable, y hasta aun sorprendente, que un mejor predictor sea corregido por el peor predictor. ;Principalmente cuando el peor predictor no agrega valor alguno al predictor tradicional<sup>4-6</sup>. </p>
      <p>Otro argumento que se utiliza a favor del s&#237;ndrome metab&#243;lico ;es la predicci&#243;n de desarrollo de diabetes. De hecho, s&#237;ndrome metab&#243;lico ;predice diabetes mejor que el Escore de Framingham<sup>5</sup>. Mientras tanto, cuando se compara s&#237;ndrome metab&#243;lico ;con modelos creados para predicci&#243;n de diabetes, estos &#250;ltimos presentan mejor capacidad predictora que el s&#237;ndrome metab&#243;lico<sup>4</sup>. Una vez m&#225;s, esto es lo esperado, pues el agrupamiento de los factores de riesgo que definen el diagn&#243;stico de s&#237;ndrome metab&#243;lico no est&#225; de acuerdo con los presupuestos cient&#237;ficos que sustentan la creaci&#243;n de modelos de predicci&#243;n de riesgo. De esta forma, para predicci&#243;n de diabetes lo m&#225;s adecuado son modelos multivariados derivados de estudios de cohorte. En este contexto, es digno de se&#241;alar que la simple ;glicemia de ayuno ;sea mejor predictor de diabetes que la definici&#243;n de ;s&#237;ndrome metab&#243;lico. Por ejemplo, en la cohorte del estudio PROSPER, el hazard ratio del s&#237;ndrome metab&#243;lico para predicci&#243;n de diabetes fue 4,4, comparado a 18,4 de la glicemia de ayuno<sup>8</sup>. </p>
      <p>Expuesto esto, se debe cuestionar porque tanto &#233;nfasis en el s&#237;ndrome metab&#243;lico. La excesiva valorizaci&#243;n de este s&#237;ndrome viene de nuestra cultura de crear r&#243;tulos de enfermedades. A ;partir de estos r&#243;tulos, ex&#225;menes complementarios, medicamentos y procedimientos complejos son justificados. Por ejemplo, la droga anorex&#237;gena Rimonabant (ya suspendida del mercado) tuvo su marketing principal basado en la "cura" del s&#237;ndrome metab&#243;lico. Al recibir el r&#243;tulo de s&#237;ndrome metab&#243;lico, un procedimiento como cirug&#237;a bari&#225;trica, en alguien sin obesidad m&#243;rbida, puede parecer justificable aun sin la validaci&#243;n cient&#237;fica necesaria. Ex&#225;menes de investigaci&#243;n de isquemia mioc&#225;rdica pueden parecer plausibles cuando son aplicados a un paciente con s&#237;ndrome metab&#243;lico, aun asintom&#225;tico. Y as&#237; sucesivamente. Es la medicalizaci&#243;n de la sociedad, inducida por r&#243;tulos de enfermedades.</p>
      <p>As&#237;, volvemos a la historia del rey. Un d&#237;a, durante un importante desfile en la plaza, al ver pasar al rey con la bella ropa, un ni&#241;o grit&#243;: &#161;El rey est&#225; desnudo! Ese ni&#241;o desenmascar&#243; la farsa creada por los sastres, abrum&#243; al rey, y principalmente a los s&#250;bditos que creyeron la mentira o tuvieron verg&#252;enza de discordar. Algunos interpretan que fue la inocencia del ni&#241;o que permiti&#243; su observaci&#243;n. En verdad, dice la leyenda que este era uno de esos ni&#241;os un tanto maliciosos. En este caso, la diferencia entre ni&#241;o y adulto que prevaleci&#243; fue el reconocimiento de la verdad desnuda. En suma, la historia del S&#237;ndrome Metab&#243;lico nos ense&#241;a que no siempre el conocimiento cient&#237;fico est&#225; basado en sus presupuestos. S&#243;lo el cuestionamiento y el debate cient&#237;fico son capaces de hacer avanzar al conocimiento.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
